What's Coming up Next on Covid-19 From Bharat Biotech For Children?

India-based Bharat Biotech will evaluate its COVID-19 vaccine in a Phase 2/3 clinical trial on children in the 2-18 age group. According to PTI report, the study will be performed on approximately 525 participants at several sites in India.

Recently, the COVID-19 vaccine developed by Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) obtained the Emergency Use Authorization (EUA) in the US for children aged 12-15 years. With the approval, the two partners became the first manufacturers to get their vaccine approved for adolescents. On 11 May 2021, Bharat Biotech’s COVID-19 vaccine, Covaxin, was recommended for a Phase 2/3 clinical trial by an expert panel on children aged between 2 to 18.

The COVID-19 Expert Committee of the CDSCO (Central Drugs Standard Control Organization) has given approval to the Indian firm to conduct the clinical study. The trial will evaluate the safety, reactogenicity as well as immunogenicity of Covaxin shots in children.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK